A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

To be part of this study, you need to meet a few simple criteria. First, you must have been officially diagnosed with Multiple Sclerosis (MS), specifically the 'relapsing' type. Second, you must have been prescribed BRIUMVI® by your doctor. You can join the study even if you haven't had your first dose yet, as long as you are about to start it.

However, there are some reasons why you might not be able to join. For example, if you've recently had certain types of vaccines (like live vaccines within the last 4 weeks or non-live vaccines within the last 2 weeks), you wouldn't be able to take part. Also, if you have an active infection, such as Hepatitis B, you wouldn't be eligible.

Finally, if you're already involved in another study looking at MS treatments, or if you're planning to take other MS modifying treatments at the same time as BRIUMVI®, then this study wouldn't be right for you.

If you decide to take part in this study, you'll simply be receiving your BRIUMVI® medicine as your doctor has already prescribed it. This study does not involve giving you a new or different medicine. It also doesn't change how you would normally take your medicine or how often you see your doctor for your MS. Because this is an 'observational' study, it means researchers will gather information about your health and your experience with BRIUMVI® from your medical records and possibly through some questionnaires.

There are no specific extra visits to a clinic just for this study. The study team will collect information during your regular doctor appointments or by checking your medical notes. The total length of your participation would depend on how long your doctor plans for you to take BRIUMVI® and for how long the study decides to collect information. You won't be asked to do anything unusual or extra apart from what your doctor would normally recommend for your MS treatment.